Bristol Myers Squibb’s Luspatercept Meets Primary Endpoint in Alpha-Thalassemia Phase 2
Bristol Myers Squibb’s luspatercept achieved positive top-line results in a registrational Phase 2 trial in adults with alpha-thalassemia, meeting its primary efficacy endpoint. The findings support plans for a regulatory submission to expand treatment options for this underserved hemoglobin disorder.
1. Phase 2 Trial Results
The registrational Phase 2 study evaluated luspatercept in adults with alpha-thalassemia, meeting its primary efficacy endpoint in top-line results. These outcomes underscore the therapy’s clinical activity in addressing anemia in this patient population.
2. Next Steps and Implications
Bristol Myers Squibb plans to engage regulatory authorities to support a filing for luspatercept’s use in alpha-thalassemia. Success in this trial enhances the company’s hematology portfolio and targets an unmet need in rare blood disorders.